asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC
Century Therapeutics
Century Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Philadelphia, USA HQ
2018 Founded
104 Employees
Public company Type
IPSC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2018
- Employees
- 104
- Programs
- 10
- Drugs
- 9
- Patents
- 39
Century Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Century Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Century Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.
- Target
- Neuronal acetylcholine receptor; alpha4/beta2
- Mechanism
- Neuronal acetylcholine receptor; alpha4/beta2 agonist
-
Development asset linked to Century Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Century Therapeutics in public FDA and regional records.
-
Development asset linked to Century Therapeutics in public FDA and regional records.
-
Development asset linked to Century Therapeutics in public FDA and regional records.